Article

Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial

2025-11-06

Abstract excerpt

RIO is an ongoing double blind randomized placebo controlled human trial in which participants that started antiretroviral therapy (ART) during primary or early-stage infection underwent treatment interruption and were randomly assigned to a group receiving one or two doses of two long acting broadly neutralizing antibodies 3BNC117-LS and 10-1074-LS (Arm A, n = 34), or saline (Arm B, n = 34). The primary clinical...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8224c038-7e81-52f8-a34c-fca4745c01be
DOI: 10.1101/2025.11.03.25339415

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trialDOI 10.1101/2025.11.03.25339415Read

T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapySemantic proximity Read

The RIO Trial: Rationale, Design, And The Role of Community Involvement In A Randomised Placebo-Controlled Trial of Antiretroviral Therapy Plus Dual Long-Acting HIV-Specific Broadly Neutralising Antibodies (bNAbs) In Participants Diagnosed With Recent HIV Infection - Study Protocol For A Two-Stage Randomised Phase II TrialSemantic proximity Read

Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trialSemantic proximity Read

HIV-1 latent reservoir size and diversity are stable following brief treatment interruption.Semantic proximity Read

Recurrent mutations drive rapid HIV escape from two broadly neutralizing antibodies <i>in vivo</i>Semantic proximity Read

Analysis of HIV-1 latent reservoir and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117Semantic proximity Read

Mechanism for evolution of diverse autologous antibodies upon broadly neutralizing antibody therapy of people with HIVSemantic proximity Read

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trialsSemantic proximity Read

Vaccine Induction of Heterologous HIV-1 Neutralizing Antibody B Cell Lineages in HumansSemantic proximity Read

Recurrent mutations drive rapid HIV escape from two broadly neutralizing antibodies in vivo.Semantic proximity Read

The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and PreventionSemantic proximity Read

Multiple Treatment Interruptions and Protecting HIV-Specific CD4 T-Cells Enables Durable CTL Response and Viral ControlSemantic proximity Read